October 17, 2024 11:12 AM EDT
News Briefing

Vi­a­tris, Lex­i­con ink li­cens­ing deal; Capri­cor’s $75M of­fer­ing

ENDPOINTS

Plus, news about Kezar Life Sci­ences and Con­cen­tra Bio­sciences:

Vi­a­tris, Lex­i­con Phar­ma­ceu­ti­cals sign li­cens­ing deal for car­dio drug: Per the agree­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

Trump picks RFK Jr. for HHS; Ab­b­Vie's psych im­plo­sion; Mer­ck tries staving off Sum­mit; and more

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times